TY - JOUR T1 - Estimating cost-benefit of quarantine length for COVID-19 mitigation JF - medRxiv DO - 10.1101/2020.04.09.20059790 SP - 2020.04.09.20059790 AU - Andreas Eilersen AU - Kim Sneppen Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/04/20/2020.04.09.20059790.abstract N2 - Background The international community has been put in an unprecedented situation by the COVID-19 pandemic. Creating models to describe and quantify alternative mitigation strategies becomes increasingly urgent.Methods In this study, we propose an agent-based model of disease transmission in a society divided into closely connected families, workplaces, and social groups. This allows us to discuss mitigation strategies, including targeted quarantine measures.Results We find that workplace and more diffuse social contacts are roughly equally important to disease spread, and that an effective lockdown must target both. We examine the cost-benefit of replacing a lockdown with tracing and quarantining contacts of the infected. Quarantine can contribute substantially to mitigation, even if it has short duration and is done within households. When reopening society, testing and quarantining is a strategy that is much cheaper in terms of lost workdays than a long lockdown of workplaces.Conclusions A targeted quarantine strategy is quite efficient with only 5 days of quarantine, and its relative effect increases when supplemented with other measures that reduce disease transmission.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis project has received funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation program under grant agreement No. 740704.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe algorithm used to carry out the simulations described in the manuscript is available upon request. ER -